Behr’s Syndrome is Typically Associated with Disturbed Mitochondrial Translation and Mutations in the C12orf65 Gene by Pyle A et al.
Behr’s Syndrome is Typically Associated with Disturbed 
Mitochondrial Translation and Mutations in the C12orf65 Gene
Angela Pyle#a, Venkateswaran Ramesh#b, Marina Bartsakouliaa, Veronika Boczonadia, 
Aurora Gomez-Durana, Agnes Herczegfalvic, Emma L. Blakelyd, Tania Smertenkoa, Jennifer 
Duffa, Gail Eglona, David Moorea, Patrick Yu Wai Mana, Konstantinos Douroudisa, Mauro 
Santibanez-Koreff, Helen Griffina, Hanns Lochmüllerf, Veronika Karcagie, Robert W. 
Taylord, Patrick F. Chinnerya,*, and Rita Horvatha,*
aWellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle 
University, Newcastle upon Tyne, UK
bDepartment of Pediatric Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals 
NHS Trust, UK
cDepartment of Pediatrics, Semmelweis University, Budapest, Hungary
dWellcome Trust Mitochondrial Research Centre, Institute for Ageing and Health, Newcastle 
University, Newcastle upon Tyne, UK
eDepartment of Molecular Genetics and Diagnostics, NIEH, Budapest, Hungary
fInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
#
 These authors contributed equally to this work.
Abstract
Background—Behr’s syndrome is a classical phenotypic description of childhood-onset optic 
atrophy combined with various neurological symptoms, including ophthalmoparesis, nystagmus, 
spastic paraparesis, ataxia, peripheral neuropathy and learning difficulties.
Objective—Here we describe 4 patients with the classical Behr’s syndrome phenotype from 3 
unrelated families who carry homozygous nonsense mutations in the C12orf65 gene encoding a 
protein involved in mitochondrial translation.
Methods—Whole exome sequencing was performed in genomic DNA and oxygen consumption 
was measured in patient cell lines.
Results—We detected 2 different homozygous C12orf65 nonsense mutations in 4 patients with a 
homogeneous clinical presentation matching the historical description of Behr’s syndrome. The 
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first symptom in all patients was childhood-onset optic atrophy, followed by spastic paraparesis, 
distal weakness, motor neuropathy and ophthalmoparesis.
Conclusions—We think that C12orf65 mutations are more frequent than previously suggested 
and screening of this gene should be considered not only in patients with mitochondrial respiratory 
chain deficiencies, but also in inherited peripheral neuropathies, spastic paraplegias and ataxias, 
especially with pre-existing optic atrophy.
Keywords
Behr’s syndrome; mitochondrial translation; optic atrophy; spastic paraplegia; peripheral 
neuropathy; ataxia
INTRODUCTION
First described by Carl Behr in 1909, classical Behr’s syndrome (MIM 210000) comprises 
childhood-onset optic atrophy combined with various neurological symptoms including 
ophthalmoparesis, nystagmus, spastic paraparesis, ataxia, peripheral neuropathy and a 
variable degree of learning difficulties [1, 2]. While the optic atrophy in these patients 
remains stable, other neurological signs progress during childhood becoming more 
prominent in the second or third decade. The majority of early cases are sporadic or show 
autosomal recessive inheritance, but some families have an autosomal dominant disorder, 
suggesting genetic heterogeneity [3].
Autosomal recessive OPA3 mutations have been identified in Iraqi Jews presenting with 
Behr’s syndrome and 3-methylglutaconic aciduria (Costeff syndrome) [4, 5] and more 
recently autosomal dominant OPA1 mutations were shown in Behr’s syndrome without 
metabolic abnormalities [6]. However the classical phenotype reported by Behr was most 
likely due to a different genetic cause.
Here, we describe 4 patients from 3 families with classical Behr’s syndrome and autosomal 
recessive mutations in the C12orf65 gene, encoding a mitochondrial protein involved in 
mitochondrial translation [7].
MATERIALS AND METHODS
Case reports
This study had institutional and ethical review board approval. All of the patients gave 
informed consent for the study and for showing their photographs.
Patient 1, a 13 year-old (y) boy and patient 2, his 7y sister were born to non-consanguineous 
Irish parents. Patient 1 had normal early development, and the first symptom was optic 
atrophy at 5y, followed by initially focal and asymmetric weakness and atrophy of the right 
arm and leg. These symptoms extended to the other side with spasticity, and he developed 
mild ataxia and learning difficulties. Currently, at age 13y he attends a special school and is 
able to walk independently with bilateral splints.
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Detailed metabolic work-up (acyl-carnitines, urinary organic acids, 3-methylglutaconic acid, 
very long chain fatty acids, phytanic acid, vitamins E, A, B12, AFP, serum electrophoresis, 
lipoproteins, lysosomal enzymes, copper, ceruloplasmin, ferritin, iron) was normal. 
Electrophysiology detected signs of anterior horn cell lesion localized to the C8/T1 region. 
MRI showed high signal intensities in the periaqueductal grey matter in the mid brain at age 
9 (Fig. 1D), but was normal at 10y.
Muscle biopsy taken at the age of 10y revealed mitochondrial myopathy and deficiencies of 
multiple respiratory chain (RC) enzymes I, II/III and IV, associated with a low mtDNA copy 
number (~10% normal values) in this tissue. No mtDNA deletions were detected in muscle 
DNA. Direct sequencing of the OPA1, TK2, RRM2B and PEO1 genes revealed no candidate 
pathogenic mutations.
On clinical examination at 13y he had hypertelorism and broad nasal bridge (Fig. 1A). He 
had bilateral optic atrophy (6/36 on both eyes), ophthalmoparesis, bilateral nystagmus and 
slow saccades, bilateral facial weakness and a slightly slurred speech. He had significant 
spasticity and deep tendon reflexes were pathologically increased. There was muscle 
wasting and weakness in the hands, with bilateral foot drop and deformed feet (Fig. 1A). He 
had mild dysmetria and a wide-based, slightly ataxic gait.
Patient 2, his younger sister (Fig. 1A) had optic atrophy since 6y, followed by mild foot 
weakness and balance problems, but attends a mainstream school at 7y. Brain MRI and 
MRS were normal at 6y. On neurological examination at 7y she had a broad nasal bridge, 
bilateral optic atrophy, ophthalmoparesis and slow saccades. She had slightly brisk deep 
tendon reflexes and a very subtle spasticity in the legs. Proximal muscle power was 
preserved, but she could not walk on heels or tiptoes. She had a slightly ataxic gait.
Patient 3 is a 22 year-old man from Northern England (Fig. 1B), second child of healthy, 
non-consanguineous parents, born after uneventful pregnancy with normal delivery. Early 
motor milestones were normal, except for tiptoe walking, and he developed visual problems 
at 5y. He complained of aches in his legs and of problems with his gait. He also had learning 
difficulties with poor concentration and memory.
Metabolic studies were normal, CK was slightly increased (379 U/L, normal 40–320). CSF 
was normal. Brain MRI at age 6y was normal, but detected bilateral, symmetric 
hyperintensities in the posterior pons and medullary region at 14y and 22y, resembling 
Leigh’s disease (Fig. 1E). Electrophysiology at age 11y showed widespread lower motor 
neuron lesion.
Muscle biopsy at the age of 10y revealed several cytochrome c oxidase (COX)-deficient 
fibers following histochemical analysis and biochemical evidence of complex IV deficiency 
at 40% of control values; the activities of complexes I, II and III were all normal. Direct 
sequencing of the OPA1 gene revealed no candidate pathogenic mutations whilst mtDNA 
rearrangements were also excluded in muscle.
Clinical examination at age 22y revealed bilateral optic atrophy (4/60 bilaterally) but normal 
eye movements. He had spasticity and bilaterally increased deep tendon reflexes with 
Pyle et al. Page 3
J Neuromuscul Dis. Author manuscript; available in PMC 2015 September 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
positive Babinski sign, but absent ankle jerks. He had severely atrophic muscles in the arms 
and legs with distal predominance and foot drop, and needed bilateral splints. He had no 
sensory or vegetative symptoms and no ataxia. He had mild intellectual disability.
Patient 4 is a 16 year-old boy, one out of four children of non-consanguineous healthy 
parents of Hungarian Roma ethnic origin. The other 3 siblings are healthy. His early motor 
development was normal, however at 1y he started to walk on tiptoes and his gait was 
clumsy. At 5y he developed visual impairment and increasing clumsiness. He developed 
bilateral foot drop and foot deformity (Fig. 1C) and his gait became increasingly difficult 
over the last 11 years. He has slight learning difficulties. Electrophysiology could not detect 
motor and sensory responses in the legs, EMG showed neurogenic atrophy. Brain MRI was 
normal at 15y.
Clinical examination at age 16y showed bilateral optic atrophy with visual acuities of 0.2 
and 0.5 in the right and left eye, respectively and slight nystagmus. There was a marked 
spasticity with distal weakness and atrophy on the lower limbs with significant foot 
deformity (Fig. 1). Deep tendon reflexes were increased, except for absent ankle jerks. He 
had a spastic-ataxic gait with foot-drop. A diagnostic muscle biopsy was not performed in 
this case.
Molecular genetics
Whole exome sequencing was performed in genomic DNA of patients 1, 2 and 3 and direct 
sequencing of C12orf65 was performed in patient 4 based on the clinical phenotype. DNA 
was isolated from lymphocytes (DNeasy®, Qiagen, Valencia, CA), fragmented and enriched 
by Illumina TruSeq™ 62 Mb exome capture, and sequenced (Illumina HiSeq 2000, 100 bp 
paired-end reads). The in-house bioinformatics pipeline included alignment to the human 
reference genome (UCSC hg19), reformatting, and variant detection (Varscan v2.2, Dindel 
v1.01), as described previously [8]. On-target variant filtering excluded those with minor 
allele frequency greater > 0.01 in several databases: dbSNP135, 1000 genomes (February 
2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, 
MD) Exome Sequencing Project (ESP) 6500 exomes, and 343 unrelated in-house controls. 
Rare homozygous and compound heterozygous variants were defined, and protein altering 
and/or putative ‘disease causing’ mutations, along with their functional annotation, were 
identified using ANNOVAR [9]. Candidate genes were prioritized if previously associated 
with a disease phenotype [10]. Putative pathogenic variants were confirmed by Sanger 
sequencing using custom-designed primers (http://frodo.wi.mit.edu) on an ABI 3130XL 
(Life Technologies, CA), allowing segregation analyses where possible. The following 
primers were used for genomic DNA analysis of C12orf65 (NM 152269): exon 2: forward: 
5′ GCATAATCTTGAGGGCAGATG-3′, reverse: 5′-GGCCCAAGCCAGAAAAATA-3′, 
exon 3: forward: 5′-GCGAACAGGTTGAATTTAATGA-3′, reverse: 5′-
CACTATAATAATGCTGGTGATGGA-3′.
Direct Sanger sequencing of the cDNA of C12orf65 was performed in patient 4 with the 
following primers: forward: 5′- GCAACCAACAAAACCAGCAA-3′ and reverse: 5′- 
CAGGACTGTTTTCACCATTGTAG-3′.
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Cell culture
Fibroblast cell cultures of two patients and controls were obtained from the Biobank of the 
Medical Research Council, Centre for Neuromuscular Diseases, Newcastle. Informed 
consent was obtained from all subjects. Fibroblasts were grown in high glucose Dulbeccos 
modified Eagle’s medium (Sigma, Poole, UK) supplemented with 10% foetal bovine serum.
Oxygen consumption was measured using Seahorse Bioscience XFe96 Extracellular Flux 
Analyzer (Seahorse Bioscience, North Billerica, MA, USA) as previously described [11] 
with some modifications. Briefly, 3×104 cells/well were seeded in 24 wells per cell line, the 
day after oxygen consumption rate (OCR), leaking respiration (LR), maximal capacity 
respiration (MCR) and not electron transport chain respiration (NMR) were determined by 
adding 1 μM oligomycin (LR), carbonyl cyanide-ptrifluoromethoxyphenylhydrazone 
(FCCP) (MCR: 2 injections of 0.5 μM and 1 μM, respectively) and 1 μM Rotenone/
antimycin (NMR), respectively. The data was corrected by the NMR and expressed as pmol 
of oxygen/min/mg of protein. The quantity of protein was measured by Bradford method.
RESULTS
DNA analysis, whole exome sequencing
Coverage and depth statistics for the exome sequencing are reported in Fig. 2A and Table 2. 
The variants in ENOSF1 and APEX2 did not segregate with the disease in the family. The 
same homozygous truncating mutation in C12orf65 (c.96_99dupATCC predicting 
p.Pro34Ilefs*25) was detected in Patients 1–3 (Table 1). The mutation segregated with the 
disease in each family, was not detected in 190 ethnically-matched control alleles, and is 
predicted to cause a complete loss of the C12orf65 protein. A homozygous c.282 G>A 
variant (predicting p.Lys94Lys) was detected in Patient 4. This mutation affects the last 
codon of exon 2, and results in the loss of a splice site with retention of intron 2 (Fig. 2). 
Unaffected family members were heterozygous for the c.282 G>A variant which was not 
detected in 200 Hungarian Roma alleles. Additional screening of the C12orf65 gene in 29 
patients with optic atrophy and additional neurological symptoms detected no pathogenic 
mutations.
Electron transport chain capacity
The Seahorse XF96 extracellular flux analyzer was used to measure oxygen consumption as 
a marker of the electron transport chain (ETC) capacity. As shown in Fig. 3, the patient cell 
lines showed a decrease in OCR when compared to controls. This difference is notably 
bigger after treating the cells with FCCP, an ETC accelerator which acts as an uncoupling 
agent transporting hydrogen ions the inner mitochondrial membrane, showing a clear ETC 
defect in the patient cell lines.
DISCUSSION
C12orf65 belongs to a family of four mitochondrial class I peptide release factors including 
mtRF1a, mtRF and ICT1, which are characterized by the presence of a conserved Gly-Gly-
Gln (GGQ) motif. From this group of genes only C12orf65 has been associated to date with 
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human disease. However, C12orf65 does not exhibit peptidyl-tRNA hydrolase activity, but 
may play a role in recycling abortive peptidyl –tRNA species, released from the ribosome 
during the elongation phase of translation [7]. Down-regulation of C12orf65 resulted in 
significant changes in the mitochondrial membrane potential and mitochondrial mass, 
indicating that it is essential for cell vitality and mitochondrial function [12].
The first report on mutations in the C12orf65 gene described 3 patients from 2 families with 
failure to thrive, nystagmus, ophthalmoparesis and psychomotor retardation in the second 
year of life and optic atrophy from 5–7y [7]. In the following years all 3 patients developed 
complex neurological symptoms including facial weakness, swallowing difficulties, motor 
neuropathy, gastrointestinal and respiratory problems, leading to severe disability (at 20y) or 
death at age 8 and 22y respectively. MRI signs were suggestive of Leigh syndrome, 
although the progression of symptoms has been slower, than in other forms of Leigh’s 
disease [7].
Recently some further papers have reported patients with mutations in C12orf65. Two 
siblings, carrying a p.Arg132* nonsense mutation, presented at age 7y with optic atrophy, 
followed by leg weakness, foot drop and spasticity. Investigation at 32y and 42y of age 
showed bilateral optic atrophy, spastic paraparesis and additional signs of motor neuropathy 
[13]. Another sibling pair with a homozygous p.Gln139* C12orf65 truncating mutation were 
reported with mild intellectual disability, spastic paraplegia and strabismus with dysmorphic 
features such as low set eye-brows [14], although the neurological description of these 
patients was limited. More recently a homozygous p.Val116* truncating mutation has been 
reported in 3 members of a large consanguineous Indian family with motor neuropathy and 
optic atrophy as characteristic signs of Charcot-Marie-Tooth disease (CMT) type 6 [15]. 
Furthermore, compound heterozygous (p.Pro34Ilefs*25 and p.Gly72*) frameshift mutations 
were present in 2 siblings who presented with optic atrophy and mild developmental delay 
and developed bilateral, symmetric lesions in the brainstem reminiscent of Leigh syndrome 
[16]. Two further homozygous mutations (p.Lys138Argfs*16 and c.282 + 2T>A) have been 
reported very recently in consanguineous families with childhood-onset optic atrophy 
accompanied by slowly progressive peripheral neuropathy and spastic paraparesis [17]. 
Most previous reports can conclusively (in hindsight) also be diagnosed as Behr’s syndrome 
except for the 2 patients in whom no neurological and ophthalmological examinations were 
noted [14].
Here we show 2 different homozygous C12orf65 nonsense mutations in 4 patients with a 
homogeneous clinical presentation matching the original historical description of Behr’s 
syndrome [1]. The first symptom in all patients was childhood-onset optic atrophy, followed 
by spastic paraparesis, distal weakness and motor neuropathy. Ophthalmoparesis, facial 
weakness and mild ataxia were also present, which symptoms could be explained by the 
periaqueductal brainstem lesion (Fig. 2). These findings show that although C12orf65 was 
thought to be associated with a “classical” mitochondrial Leigh syndrome, hereditary spastic 
paraplegia (SPG55) or complicated CMT (CMT6), a detailed re-analysis of the phenotypes 
described in these previous reports revealed that all may be compatible with Behr’s 
syndrome.
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Our study of three independent families with Behr’s syndrome strongly suggests that 
C12orf65 is an important causative gene that underlies this distinct clinical phenotype.
The clinical presentation of C12orf65 mutations is different from other genetic forms of 
Behr’s syndrome. Autosomal recessive OPA3 mutations have been identified in patients 
presenting with 3-methylglutaconic aciduria, optic atrophy and/or choreoathetoid movement 
disorder with onset before 10 years of age (Costeff syndrome) and spastic paraparesis, mild 
ataxia and occassional mild cognitive deficit may only develop later in the second decade [4, 
5]. Autosomal dominant OPA1 mutations may only occassionally present as Behr’s 
syndrome [6], and although the optic atrophy is usually the first symptom, other 
neurological signs may not develop at all or appear only in adult age [18]. We suggest that 
the classical phenotype reported by Behr was most likely due to mutations in the C12orf65 
gene, and this genetic cause is the most frequent cause of Behr’s syndrome in patients of 
different ethnic origin.
As an unexpected finding we detected low mtDNA copy number, but no mtDNA deletions 
in skeletal muscle of 1 patient. No data are available about mtDNA copy number analysis in 
any other previously reported patients. The presence of mtDNA depletion in muscle DNA of 
patient 1 is intriguing. It may reflect down-regulation of the mitochondrial mass, and it is 
also possible that the primary molecular defect in C12orf65 causes the combined respiratory 
chain defect at least in part through an effect on mtDNA copy number. Further studies are 
required to confirm this observation in additional cases.
In summary, Behr’s syndrome due to C12orf65 mutations is a clinically recognizable 
disease presentation and should be considered not only in multiple mitochondrial respiratory 
chain deficiencies, but also in the differential diagnosis of inherited peripheral neuropathies, 
spastic paraplegias and ataxias, especially with pre-existing optic atrophy.
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Fig. 1. 
Clinical presentation and brain MRI of patients carrying homozygous nonsense mutations in 
the C12orf65 gene. Patient 1 and 2 (A), patient 3 (B), patient 4 (C), brain MRI of patients 1 
(D) and 3 (E) detected bilateral, symmetric hyperintensities in the posterior pons and 
medullary region.
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Fig. 2. 
A: Exome coverage and depth statistics. (a) Variants with position within targets (Illumina 
Truseq 62 Mb)+/−500 bp, seen on both (Forward & Reverse) strands and (SBVs only) 
variant allele frequency > 24%, (b) Rare/novel variants (homozygous MAF < 0.01, 
compound heterozygous MAF product < 0.0001 and single heterozygous MAF < 0.001) 
with exclusion of common variants found to be shared in an in-house panel of 394 
individuals, 1000 Genomes and NHLBI-ESP 6500 databases. B: Schematic structure of 
C12orf65, showing the localisation of the RF-1 domain, position of identified mutations and 
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the exon structure. Exome sequencing identified pathogenic C12orf65 mutations in 4 
patients. C: Schematic structure of C12orf65 cDNA showing the splice defect (ii) caused by 
the c.282 G>A mutation in Patient 4. D: Agarose gel showing the amplification of cDNA in 
patient 4 and in his mother, i) normal splicing producing a 160 bp product, ii) mutation 
causing intron 2 to be retained giving a larger band of 478 bp.
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Fig. 3. 
Oxygen consumption in fibroblasts, white and stripped bars represent the mean values from 
controls (C1 and C2) and patients (P1 and P2), respectively. Corrected oxygen consumption 
by the non mitochondrial respiration and mg of protein is represented as oxygen 
consumption rate (OCR), leaking respiration (LR) and maximal capacity respiration (MCR), 
respectively. The mean value for OCR respiration in control fibroblasts has been set to 
100%. OCR: Controls, 100.0 ± 3.38% (2); P1, 64.9 ± 7.06% (24); P2, 77.82 ± 12.41% (24) 
LR: Controls, 12.24 ± 3.54% (2); P1, 8.15 ± 7.66% (24); P2, 12.70 ± 19.54% (24) MCR: 
Controls, 327.97 ±48.93% (2); P1, 137.70 ± 21.11% (24); P2, 174.63 ± 27.14% (24). p 
values are shown in the figure.
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